Amneal Pharmaceuticals (AMRX) Releases FY18 Earnings Guidance

Amneal Pharmaceuticals (NYSE:AMRX) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.90-0.92 for the period, compared to the Thomson Reuters consensus estimate of $0.95.

Shares of NYSE:AMRX opened at $20.07 on Friday. Amneal Pharmaceuticals has a 52 week low of $13.47 and a 52 week high of $24.48. The company has a debt-to-equity ratio of 2.85, a quick ratio of 1.25 and a current ratio of 2.01. The firm has a market capitalization of $5.70 billion, a PE ratio of 31.86, a PEG ratio of 0.90 and a beta of 1.56.

Amneal Pharmaceuticals (NYSE:AMRX) last released its quarterly earnings results on Wednesday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.01. Amneal Pharmaceuticals had a negative return on equity of 8.74% and a negative net margin of 52.94%. The business had revenue of $476.50 million during the quarter, compared to analysts’ expectations of $486.01 million. The firm’s quarterly revenue was up 87.1% compared to the same quarter last year. On average, sell-side analysts forecast that Amneal Pharmaceuticals will post 0.91 EPS for the current year.

A number of research firms recently issued reports on AMRX. ValuEngine raised Amneal Pharmaceuticals from a sell rating to a hold rating in a report on Friday, August 3rd. Morgan Stanley cut their price target on Amneal Pharmaceuticals from $26.00 to $24.00 and set an overweight rating for the company in a report on Wednesday, October 3rd. Royal Bank of Canada raised Amneal Pharmaceuticals from a sector perform rating to an outperform rating in a report on Monday, August 13th. SunTrust Banks cut Amneal Pharmaceuticals from a buy rating to a hold rating and set a $15.00 price target for the company. in a report on Tuesday, October 16th. Finally, Zacks Investment Research cut Amneal Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 17th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $22.75.

In other Amneal Pharmaceuticals news, SVP Nikita Shah sold 50,000 shares of the business’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $23.46, for a total transaction of $1,173,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Bryan M. Reasons sold 11,698 shares of the business’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total value of $276,657.70. The disclosure for this sale can be found here. Insiders own 3.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.

Recommended Story: How Investors Use a Balance Sheet

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply